Inhibitory effects of Calocybe indica macrofungi on experimental benign prostatic hyperplasia in rats

Document Type : Short Communication


1 Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, University of Nigeria, 410001, Nsukka, Nigeria

2 Institute for Drug Herbal Medicine Excipients Research and Development, Department of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria

3 Department of Biochemistry, School of Life Sciences, Modibbo Adama University of Technology Yola, Yola, Nigeria


Objective(s): This study was designed to investigate the protective effects of Calocybe indica extract on testosterone-induced benign prostatic hyperplasia in rats. 
Materials and Methods: In this study, 60 adult Sprague Dawley rats were randomly divided into six equal groups, one group served as the normal control, five of the groups were administered subcutaneous testosterone propionate for 28 days to induce benign prostatic hyperplasia, three of the five groups were simultaneously administered three graded doses of C. indica extract while one group was administered finasteride as the standard drug and the other left as untreated BPH model group given testosterone propionate only. BPH in the prostate gland was detected through gross appearance, prostate weight, and biochemical and histopathological analyses.
Results: Increased prostate weight, serum prostate-specific antigen (PSA), and epithelial thickness were observed in the untreated testosterone-induced BPH model. Administration of finasteride and C. indica extract led to a reduction in prostate weight, prostatic index, serum PSA, serum levels of testosterone, and prostatic epithelial thickness, and increased luminal diameter. 
Conclusion: Administration of C. indica extract suppressed the pathophysiological effects of benign prostatic hyperplasia in rats. Thus, C. indica mushroom is a potential pharmacological candidate for the management of BPH in man or dogs.


1.    Glina S, Roehrborn CG, Esen A, Plekhanov A, Sorsaburu S, Henneges C,  et al. Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride. J Sex Med 2015; 12: 129-138.
2.    Makchit G. Prevalence of prostatic disorders in dogs in Jos, Plateau State, Nigeria.  Saudi J Med Pharm Sci 2017; 3: 745-747.
3.    Homma Y, Gotoh M, Kawauchi A, Kojima Y, Masumori N, Nagai A. et al. Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia. Int J Urol 2017; 24: 716-729. 
4.    Langan RC. Benign Prostatic Hyperplasia. Prim Care Clin  Office Prac 2019; 46: 223–232. 
5.    Madersbacher S, Sampson N, Culig Z. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: A mini-review. Gerontology 2019; 65: 458-464.
6.    Mitsunari K, Miyata Y, Matsuo T, Mukae Y, Otsubo A, Harada J, et al. Pharmacological effects and potential clinical usefulness of polyphenols in benign prostatic hyperplasia. Molecules 2021; 26: 450. 
7.    Ruetten H, Wehber M, Murphy M, Cole C, Sandhu S, Oakes S, et al. A retrospective review of canine benign prostatic hyperplasia with and without prostatitis. Clin Theriogenology 2021; 13: 360-366. 
8.    Flores RB, Angrimani D, Rui BR, Brito MM, Abreu RA, Vannucchi CI. The influence of benign prostatic hyperplasia on sperm morphological features and sperm DNA integrity in dogs. Reprod Domest Anim 2017; 52: 310-315. 
9.    Polisca A, Troisi A, Fontaine E, Menchetti L, Fontbonne A. A retrospective study of canine prostatic diseases from 2002 to 2009 at the Alfort Veterinary College in France. Theriogenology 2016; 85: 835-840. 
10.    Van Asseldonk B, Barkin J, Elterman DS. Medical therapy for benign prostatic hyperplasia: a review. Can J Urol 2015; 22:7-17. 
11.    Mobley D, Feibus A, Baum N. Benign prostatic hyperplasia and urinary symptoms: Evaluation and treatment. Postgrad Med 2015; 127: 301-307. 
12.    Csikós E, Horváth A, Ács K, Papp N, Balázs VL, Dolenc MS, et al. Treatment of benign prostatic hyperplasia by natural drugs. Molecules 2021; 26: 1-32. 
13.    Russo GI, Broggi G, Cocci A, Capogrosso P, Falcone M, Sokolakis I, et al. Relationship between dietary patterns with benign prostatic hyperplasia and erectile dysfunction: A collaborative review. Nutrients 2021; 13: 1-12. 
14.    Kim EH, Larson JA, Andriole GL. Management of benign prostatic hyperplasia. Annu Rev Med 2016; 67:137-151. 
15.    Dearakhshandeh N, Mogheiseh A, Nazifi S, Ahrari Khafi MS, Abbaszadeh Hasiri M, Golchin-Rad K. Treatment of experimentally induced benign prostatic hyperplasia with Tadalafil and castration in dogs. Theriogenology 2020; 142:236-245. 
16.    Gacci M, Andersson KE, Chapple C, Maggi M, Mirone V, Oelke M. et al. Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2016; 70:124-133.
17.    Bortnick E, Brown C, Simma-Chiang V, Kaplan SA. Modern best practice in the management of benign prostatic hyperplasia in the elderly. Ther Adv Urol 2020;12: 1-11. 
18.    Jiwrajka M, Yaxley W, Ranasinghe S, Perera M, Roberts MJ, Yaxley J. Drugs for benign prostatic hypertrophy. Aust Prescr 2018; 41: 150-153.
19.    Archer M, Dogra N, Dovey Z, Ganta T, Jang HS, Khusid JA, et al. Role of α- and β-adrenergic signaling in phenotypic targeting: Significance in benign and malignant urologic disease. Cell Commun Signal 2021; 19: 78-98. 
20.    Yu ZJ, Yan HL, Xu FH, Chao HC, Deng LH, Xu XD, et al. Efficacy and side effects of drugs commonly used for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Front Pharmacol 2020; 11: 658-674. 
21.    Leong JY, Patel AS, Ramasamy R. Minimizing sexual dysfunction in BPH surgery. Curr Sex Health Rep 2019;11:190-200. 
22.    Soans J, Vazirian-Zadeh M, Kum F, Dhariwal R, Breish MO, Singh S, et al. Can surgical treatment for benign prostatic hyperplasia improve sexual function? A systematic review. Aging Male 2020; 23:770-779. 
23.    Kwon Y. Use of saw palmetto (Serenoa repens) extract for benign prostatic hyperplasia. Food Sci Biotechnol 2019; 28: 1599-1606.
24.    Akbari F, Azadbakht M, Gaurav A, Azimi F, Mahdizadeh Z, Vahedi L, et al. Evaluation of the therapeutic effect of the traditional herbal medicine atrifil and oshagh gum on testosterone-induced benign prostatic hyperplasia in wistar rats. Adv Urol 2022; 2022: 1-14. 
25.    Eleazu C, Eleazu K, Kalu W. Management of benign prostatic hyperplasia: Could dietary polyphenols be an alternative to existing therapies? Front Pharmacol 2017; 8: 1-11. 
26.    Ghosh SK. Study of anticancer effect of Calocybe indica mushroom on breast cancer cell line and human Ewings sarcoma cancer cell lines. NY Sci J 2015; 8: 10-5.
27.    Subbiah KA, Balan V. A comprehensive review of tropical milky white mushroom (Calocybe indica P&C). Mycobiology. 2015; 43:184-194. 
28.    Ghosh S, Khatua S, Dasgupta A, Acharya K. Crude polysaccharide from the milky mushroom, Calocybe indica, modulates innate immunity of macropha ge cells by triggering MyD88-dependent TLR4/NF-κB pathway. J Pharm Pharmacol 2021; 73: 70-81. 
29.    Shashikant M, Bains A, Chawla P, Fogarasi M, Fogarasi S. The current status, bioactivity, food, and pharmaceutical approaches of Calocybe indica: A review. Anti-oxidants (Basel) 2022; 11: 1145-1160. 
30.    National Research Council. Committee for the update of the guide for the care and use of laboratory animals, guide for the care and use of laboratory animals, 8th edn. National Academies Press; 2011.
31.    Organization for Economic Cooperation and Development, Test No. 423:  Acute oral toxicity-acute toxic class method. Organization for Economic Cooperation and Development Guidelines for the Testing of Chemicals, Section 4, OECD Publishing; 2003.
32.    Jeon WY, Kim OS, Seo CS, Jin SE, Kim JA, Shin HK, et al. Inhibitory effects of Ponciri fructus on testosterone-induced benign prostatic hyperplasia in rats. BMC Complement Altern Med 2017; 17: 384-393. 
33.    Ko JW, Park SW, Shin NR, Kim WI, Kim JC, Shin IS.  et al. Inhibitory effects of Pycnogenol®, a pine bark extract, in a rat model of testosterone propionate-induced benign prostatic hyperplasia. Lab Anim Res 2018; 34: 111-117. 
34.    Suvarna SK, Layton C, Bancroft JD. Bancroft’s Theory and Practice of Histological Techniques. 8th.edn. Elsevier; 2019. 
35.    Kim SK, Seok H, Park HJ, Jeon HS, Kang SW, Lee BC, et al. Inhibitory effect of curcumin on testosterone induced benign prostatic hyperplasia rat model. BMC Complement Altern Med 2015; 15: 380-386. 
36.    Park E, Lee MY, Jeon WY, Lee N, Seo CS, Shin HK. Inhibitory effect of Yongdamsagan-Tang water extract, a traditional herbal formula on testosterone-induced benign prostatic hyperplasia in rats. Evid Based Complement Alternat Med 2016; 2016: 1-8. 
37.    Kwon Y. Use of saw palmetto (Serenoa repens) extract for benign prostatic hyperplasia. Food Sci Biotechnol 2019; 28: 1599-1606. 
38.    Jena AK, Vasisht K, Sharma N, Kaur R, Dhingra MS, Karan M. Amelioration of testosterone induced benign prostatic hyperplasia by Prunus species. J Ethnopharmacol 2016; 190: 33-45. 
39.    Huang JJ, Cai Y, Yi YZ, Huang MY, Zhu L, He F, et al. Pharmaceutical evaluation of naftopidil enantiomers: Rat functional assays in vitro and estrogen/androgen induced rat benign prostatic hyperplasia model in vivo. Eur J Pharmacol 2016; 791: 473-481. 
40.    Raafat M, Kamel AA, Shehata AH, Ahmed AF, Bayoumi AMA, Moussa RA, et al. Aescin protects against experimental benign prostatic hyperplasia and preserves prostate histomorphology in rats via suppression of inflammatory cytokines and COX-2. Pharmaceuticals (Basel) 2022; 15: 130-148. 
41.    Foo KT. Pathophysiology of clinical benign prostatic hyperplasia. Asian J Urol 2017; 4: 152-157.
42.    Lesovaya EA, Kirsanov KI, Antoshina EE, Trukhanova LS, Gorkova TG, Shipaeva EV, et al. Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats. Oncotarget. 2015; 6: 9718-9727.
43.    Madersbacher S, Sampson N, Culig Z. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: A mini-review. Gerontology 2019; 65: 458-464.
44.    Trujillo-Rojas L, Fernández-Novell JM, Blanco-Prieto O, et al. Rat age-related benign prostate hyperplasia is concomitant with an increase in the secretion of low ramified α-glycosydic polysaccharides. Theriogenology 2022;189: 150-157. 
45.    Nahata A, Dixit VK. Ganoderma lucidum is an inhibitor of testosterone-induced prostatic hyperplasia in rats. Andrologia 2012;44: 160-174.  
46.    Kim YN, Kim MS, Chun SS, Choi JH. Effect of Phellius linteus water extract on benign prostatic hyperplasia. Nutr Res Pract 2013; 7: 172-177. 
47.    Choi YJ, Kim EK, Fan M, Tang Y, Hwang YJ, Sung SH. Effect of Paecilomyces tenuipes extract on testosterone-induced benign prostatic hyperplasia in Sprague-Dawley rats. Int J Environ Res Public Health 2019; 16: 3764-3773.